COST EFFECTIVENESS OF ZOLEDRONIC ACID IN THE PREVENTION OF SKELETAL RELATED EVENTS IN RENAL CELL CARCINOMA PATIENTS WITH BONE METASTASES: AN EXPLORATORY ANALYSIS FOR FRANCE

被引：0

作者：

Botteman, M. ^{[1
]}

Stephens, J.

Foley, I.

Kaura, S. ^{[2
]}

机构：

[1] Pharmerit N Amer LLC, Hlth Econ, Bethesda, MD USA

[2] Novartis Pharmaceut, E Hanover, NJ USA

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：201 / 202

页数：2

共 50 条

[21] COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID THERAPY FOR RENAL CELL CARCINOMA (RCC) PATIENTS WITH BONE METASTASES IN FRENCH, GERMAN, AND THE UK POPULATIONS
Botteman, M. F.
Kaura, S.
VALUE IN HEALTH, 2009, 12 (07) : A270 - A271
[22] Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma
Vincenzi, B
Santini, D
La Cesa, A
Tonini, G
CANCER, 2004, 100 (09) : 1987 - 1988
[23] Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma
Lipton, A
Zheng, M
Seaman, J
CANCER, 2003, 98 (05) : 962 - 969
[24] A COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER IN 4 EUROPEAN COUNTRIES
Botteman, M.
Carter, J.
Kaura, S.
VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
[25] Analysis of the cost-effectivenss of zoledronic acid for the prevention of skeletal-related events prostate cancer and bone metastases: A comparison across four European countries
Botteman, M.
Logman, F.
Kaura, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[26] Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
Stopeck, Alison
Brufsky, Adam
Kennedy, Lisa
Bhatta, Sumi
Bhowmik, Debajyoti
Buchanan, Jacqueline
Despiegel, Nicolas
Hechmati, Guy
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 37 - 47
[27] Effect of Bisphosphonates on Skeletal Related Events in Long Bone Metastases of Renal Cell Carcinoma: A Review
van Broekhoven, Danique L. M.
Dootjes, Lisa W.
van der Veldt, Astrid
Zillikens, Carola
van Oldenrijk, Jakob
CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : E190 - E197
[28] Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer
Saad, Fred
Eastham, James A.
SEMINARS IN ONCOLOGY, 2010, 37 (03) : S38 - S44
[29] Efficacy of zoledronic acid in the treatment of bone metastases secondary to renal cell carcinoma
Schulman, CC
EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (05) : 40 - 45
[30] Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma - Author reply
Lipton, A
CANCER, 2004, 100 (09) : 1988 - 1988

← 1 2 3 4 5 →